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Abstract The interactions of the peptide RP135a (RKSI- 
RIQRGPGRAFVT), corresponding to residues 311-326 of 
gpl20 of HIV-ImB, with the anti-gpl20 HIV-ImB neutralizing 
antibody 0.5,8 were studied by NMR. The NOESY difference 
spectra measured using specifically deuterated erivatives of the 
peptide show exclusively the interactions of the deuterated resi- 
dues both within the bound peptide and with the Fab fragment of 
the antibody. These measurements reveal hydrophobie interac- 
tions within the bound peptide between Ile-4, Ile-6 and Val-15 that 
create a 12-residue loop with these residues at the base and the 
conserved GPGR sequence at its top. 
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I. Introduction 
The principal neutralizing determinant (PND) of the human 
immunodeficiency virus type 1 (HIV-1) has been mapped to a 
24-amino acid-long sequence (NNTRKSIR IQRGPG-  
RAFVT IGKIG)  corresponding to residues 308 331 of the 
virus envelope glycoprotein, gpl20 [1-3]. This sequence, de- 
noted RP135, is part of the third hypervariable region (V3) 
which forms a disulfide cross-linked 36-residue loop [4]. RP135 
and its shorter derivatives were found to elicit HIV neutralizing 
antibodies, thus demonstrating their potential use in a peptide 
based vaccine [2]. The 0.5fl antibody is a very potent strain- 
specific virus neutralizing antibody which was raised against 
gpl20 of HIV-I ,m [5]. Passive immunization with a chimeric 
antibody which contains the intact variable regions of 0.5fl was 
found to protect chimpanzees from HIV infection [6]. The anti- 
body 0.5,8 binds gpl20 and the peptide RP135 with comparable 
affinities (2 × 108 and 7 × 107 M ~, respectively) [7]. 
The structure of gpl20 is not known and there is no struc- 
tural information on anti-gp 120 antibodies and their complexes 
with their corresponding antigens. To study the conformation 
of PND peptides as they are recognized by anti-gpl20 virus 
neutralizing antibodies directed against he V3 loop, it is possi- 
ble to use NMR and especially two-dimensional NOE spectros- 
copy (NOESY). NOESY measurements detect interactions be- 
tween hydrogen uclei (protons), that are separated by up to 
5 A [8,9]. In the two-dimensional spectrum these interactions 
are manifested by cross-peaks that are characterized by the 
resonance frequencies of the two interacting nuclei. As shown 
in the spectra of the 0.5,8 Fab fragment (50 kDa) presented in 
Fig. 1A and B, NOESY spectra of large proteins suffer from 
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lack of resolution due to the large number of protons in the 
molecule and the broadening of their individual resonances that 
occurs as the molecular weight of the protein increases. More- 
over, techniques that are used to assign resonances to the cor- 
responding protein protons (sequential assignment) are cur- 
rently not applicable for proteins of the size of the Fab frag- 
ment of the antibody [9,10]. Transferred NOE difference spec- 
troscopy has been used to study antibody peptide complexes 
and to obtain simplified spectra that show exclusively cross- 
peaks due to antibody peptide interactions and interactions 
within the bound peptide [11]. Unfortunately, this technique is
not applicable for the 0.5fl RP135 complex due to its very slow 
dissociation rate [12]. In such case difference spectra calcula- 
tions using deuterated peptides could be applicable, as was 
demonstrated in studies of pepsin interactions with a tri-peptide 
inhibitor [13]. 
2. Materials and methods 
2.1. Peptides and Fab 
The peptide RPI35a (RKSIRIQRGPGRAFVT) was synthesized 
and purified as described previously [12]. Perdeuterated L-amino acids 
(isoleucine, proline, alanine and valine) and L-phenyl-ds-alanine w re 
obtained from MSD Isotopes, Canada. Minimum isotopic purity of the 
deuterated amino acids was 98% 2H. For peptide synthesis all deuter- 
ated amino acids were protected by t-butyloxycarbonyl group (t-boc). 
Protected euterated amino acids were synthesized and purified by Oz 
Chemicals, Israel. Six derivatives of RP135a were prepared by specific 
deuteration ata single position (Ile-4, Ile-6, Pro-10, Ala-13, Phe-14 or 
Val-15). Preparation and purification of the Fab fragment was de- 
scribed previously [12]. 
2.2. NMR spectroscopy 
The two samples used for each difference spectrum easurement 
contained the same concentration f the Fab-RP135a complex, using 
Fab from the same cleavage batch. Concentration f the complex for 
all difference spectra was 1 1.4 mM in l0 mM phosphate-buffered D20 
pH 7.15 (meter eading) containing 0.05% NaN 3. NOESY spectra were 
measured at 315 K on a Bruker AM500 with a 70 ms mixing period. 
The residual HOD signal was suppressed by gated irradiation. A total 
of 256 transients were acquired in the tt domain with 80 × 2K free 
induction decays acquired for each t~ value. To obviate the use of a 
phase correction in the F~ dimension, the sampling delay, dO, was set 
to dO = [IN0/2]- [2PW/Ir] where IN0 is the dwell time in the F~ dimen- 
sion and PW is the length of the 90 ° pulse (Bax et al., 199l). The data 
was zero filled in the F t dimension, multiplied in both dimensions by 
a square sine bell window shifted by 60 ° and then Fourier transformed 
in both dimensions. To yield minimal distortions inthe difference spec- 
trum baseline, the phases of the two spectra (NOESY of Fab with 
unlabeled peptide and NOESY of Fab with specifically deuterated 
peptide) were very carefully adjusted prior to subtraction. By matching 
pairs of rows from the two spectra, adifference factor is chosen (usually 
1.0 or very close to 2", where n is a scaling factor between the spectra) 
to minimize the number of both positive and negative cross-peaks and 
to obtain a fiat baseline Typically, a baseline correction is further 
applied around the HDO resonance of the difference spectrum. 
To examine the effect of the mixing time on the signal-to-noise ratio 
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in the NOESY and the difference spectrum we measured the NOESY 
spectra of Fab complex with unlabeled peptide and with a peptide in 
which Val-15 was deuterated attwo different mixing times: 40 ms and 
70 ms. The signal-to-noise ratios in the NOESY spectrum (of the re- 
solved cross-peaks of Ile-4) and in the NOESY difference spectrum 
(Val-15 cross-peaks) were 30% higher with 70 ms mixing time in com- 
parison with the spectra measured using 40 ms mixing. Because of the 
considerable improvement in the signal-to-noise ratio all other NOESY 
spectra were recorded with 70 ms mixing. The limited number of ob- 
served cross-peaks, and the observation that within a given peptide 
residue only some of the protons give rise to NOE cross-peaks with Fab 
protons (as shown for Ile-4 in Fig. 1D), and that these cross-peaks vary 
in their intensity, indicate that spin diffusion is rather limited. Perhaps 
the higher temperature, and the relatively low concentration used (1,2 
mM of Fab) helped to decrease the sample viscosity and subsequently 
the rotational correlation time of the Fab molecule, thus decreasing 
spin diffusion effects. Moreover, the signal-to-noise in the difference 
spectra does not enable the observation of weak cross-peaks that could 
potentially arise from spin-diffusion. 
3. Resu l ts  
To study 0.5fl interactions with the PND of HIV-lmB we 
used the peptide RP135a (RKS IR IQRGPGRAFVT)  which 
contains the epitope recognized by the antibody [12]. The differ- 
ence between the one-dimensional (1D) ~H NMR spectrum of 
the Fab complex with the unlabeled peptide and that of the Fab 
complex with a specifically deuterated peptide shows the reso- 
nances of the labeled residue in the bound peptide (data not 
shown). The difference between the NOESY spectrum of the 
Fab complex with the unlabeled peptide and the NOESY spec- 
trum of the Fab complex with a specifically deuterated peptide 
shows the NOE cross-peaks of the labeled residue. The NOESY 
difference spectrum and the 1D difference spectrum measured 
for each specifically deuterated peptide are used together to 
assign the resonances of the labeled residue to the correspond- 
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Fig. 1. A comparison between regions of the NOESY spectrum of the 0.5fl Fab complex with the peptide RPI35a (RKSIRIQRGPGRAFVT) 
corresponding to residues 311-326 of gp 120 of HIV- 1 ~lJ~ (Fig. 1A and B) and the difference between this spectrum and the spectrum of the complex 
in which Ile-4 of the peptide was deuterated (Fig. 1C and 1D). The difference spectrum shows the NOE cross-peaks of the deuterated residue. The 
location of lle-4 resonances are marked on the y-axis. The arrows in Fig. 1A mark the locations of Ile-4 cross-peaks observed inthe difference spectrum 
(Fig. 1C). Cross-peaks due to intra-residue interactions are marked by I4, interactions within the bound peptide are labeled with the the symbol of 
the proton interacting with Ile-4 i.e. Vl5fl, and cross-peaks that could be due to either RP135a/Fab interactions or interactions within RP135a are 
marked as such (i.e. Fab/RP135a). 
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Fig. 2. The difference between the NOESY spectrum of 0.5,8 Fab complex with the peptide RPI35a (RKSIRIQRGPGRAFVT) and the spectrum 
of the Fab complex with a peptide molecule in which a specific peptide residue has been deuterated: (A) Ile-6 and (B) Val-15. The difference spectrum 
shows the NOE cross-peaks of the deuterated residue in the aliphatic region of the spectrum• The locations of the resonances of the deuterated residues 
are marked on the y-axis and cross-peaks are labeled as in Fig. 1. The inserts give a blow-up of the marked cross-peaks. 
ing protons and to discern NOESY cross-peaks due to intra- 
residue interactions from cross-peaks due to inter-residue inter- 
actions. The partial assignment of the bound peptide reso- 
nances is summarized in Table 1. 
The NOESY difference spectrum easured for a Fab com- 
plex with a peptide in which Ile-4 was deuterated is shown in 
Fig. 1C and D. This spectrum exhibits with a remarkable sig- 
nal-to-noise ratio only NOE cross-peaks of Ile-4; all other 
cross-peaks not involving Ile-4 are cancelled out. All cross- 
peaks in Fig. 1 C, except one, were assigned to Ile-4 interactions 
with aromatic protons of the Fab. On the basis of its chemical 
shifts, the cross-peak at (4.79, 7.02 ppm) could be assigned to 
interaction with the Fab or with C,H of Phe-14 ofRP135a. Fig. 
1D reveals interactions of Ile-4 ~CH3 with three peptide pro- 
tons: Ile-6 yCH3, Ile-6 ~H and Val-15 fill. Two additional 
cross-peaks in Fig. 1D (0.40, 4.14 and 1.70, 4.14 ppm) are due 
to lle-4 interactions with Fab protons or yet unassigned peptide 
protons. 
Table 1 
Resonance assignments of RPI35a bound to the 0.5,8 antibody 
Residue ~H flH others 
Ile-4 4.79 
lle-6 4.24 
Pro-10 4.19 
Ala-13 3.97 
Phe-14 5.01 
Val-15 4.42 
1.71 yCH2: 0.9, 0.57; 7CH3: 0.39; 
~CH3:0.09 
1.89 yCH2: 1.49, 1.37; yCH3: 1.03; 
¢~CH3:0.86 
8CH2: 3.24, 3.02 
1.3 
2.95, C6H: 7.14; C,H: 7.02 
2.73 
2.12 yCH3:0.90 
Chemical shifts are given in ppm relative to 3-(trimethylsilyl)-propi- 
onic-2,2,3,3-d4 acid, sodium salt. 
According to the difference spectrum presented in Fig. 2A, 
yCH3 of Ile-6 interacts with three peptide protons: Ile-4 ~CH3, 
Val-15 yCH3 and Val-15 fill. Intra-peptide interactions are 
observed also between Ile-6 flH and Val-15 yCH3 and between 
Ile-6 ~H and both Ile-4 ~H and Val-15 yCH3. According to the 
difference spectrum presented in Fig. 2B Val-15 protons are 
involved in a number of long range interactions within the 
bound peptide: (a) Val-15 yCH3 interacts with the following 
peptide protons: Ile-4 ~CH3, Ile-6 ~H, lle-6 fill, Ile-6 yCH3 and 
one of the Ile-6 yCH2 protons; (b) Val-15 flH interacts with 
Ile-6 ~CH 3 and Ile-6 ~'CH3; and (c) Val-15 ~H interacts with 
Ile-6 ~CH 3. The observation that most of the interactions be- 
tween Ile-4, Ile-6 and Val-15 appear twice in the presented 
spectra confirms our assignment; i.e. an interaction between 
Val-15 and Ile-6 appears once in the difference spectrum eas- 
ured for a Fab complex with a peptide in which Val-15 is 
deuterated and once in a difference spectrum easured for Fab 
complex with RP135a in which Ile-6 is deuterated. 
Ile-6, Pro-10 and Phe-14 were found to interact with aro- 
matic protons of the Fab (data not shown). The aromatic pro- 
tons of Phe-14 and the methyl protons of Ala-13 were found 
to interact with non-aromatic protons of the Fab or yet uniden- 
tified protons of RP135a (data not shown). No additional inter- 
actions within the bound peptide could be assigned. 
4. Discussion 
The extensive network of hydrophobic interactions in the 
bound peptide between Ile-4, Ile-6 and Val-15 indicates that the 
sequence IRIQRGPGRAFV, corresponding to residues 314- 
325 of HIV-Inm gpl20, forms a 12 residue loop with Ile-4, Ile-6 
and Val-15 at the base and the conserved GPGR sequence at 
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Fig. 3. A schematic llustration of the 12-residue loop formed within the 
V3 peptide RP 135a bound to the anti-gp 120 HIV-neutralizing antibody 
0.5ft. The arrows mark the observed interactions. 
the top as schematically illustrated in Fig. 3. This 12-residue 
loop formed by non-covalent interactions i part of the larger 
36-residue V3 loop formed by a disulfide bridge between Cys- 
303 and Cys-338 of gpl20 [4]. The hydrophobic interactions 
observed in RP135a bound to the anti-gpl20 antibody 0.5,8 
were not observed in free RP135 [15] nor were they observed 
in the crystal structure of complexes of antibodies raised 
against PND peptides of the MN strain [16,17]. The PND 
peptide of the MN strain (RP142) shares 52% identity with 
RP135 [15]. The two anti-MN peptide antibodies that were 
studied by X-ray crystallography recognize only 7-residue pi- 
topes, considerably shorter than the 14-16 residue pitope rec- 
ognized by 0.5fl [12]. Anti-gpl20 antibodies have not been stud- 
ied before neither by X-ray crystallography nor by NMR spec- 
troscopy. Our study demonstrates the benefits of using anti- 
gpl20 antibodies that recognize a large epitope to obtain the 
global conformation of the V3 loop. As the 0.5fl antibody was 
raised against gp120, it is expected that the conformation of the 
flexible PND peptide bound to the antibody is similar to the 
conformation of the corresponding part of gpl20 when bound 
to the same antibody. In this case the more rigid antibody 
raised against gpl20 will serve as a template for the folding of 
the peptide. Peptides corresponding in sequence to segments of 
the V3 loop have been used to elicit HIV-I neutralizing anti- 
bodies [2]. In view of our findings, it is possible that chemically 
constrained synthetic peptides that contain the 12-residue loop 
will be more efficient han flexible peptides in eliciting highly 
cross-reactive and potent HIV-I neutralizing antibodies. 
Ile-4 and Ile-6 of RPI35a correspond to Ile-314 and Ile-316 
of gpl20, which are conserved in 94% and 82% of gpl20 se- 
quences, respectively [18]. In only 1.6% and 3.2% of gpl20 
sequences do polar residues appear in positions 314 and 316, 
respectively. ¥a1-15 of RP135a corresponds to Val-325 of 
gpl20. Although valine is not the most common residue in 
position 325, 94% of gpl20 sequences have a hydrophobic 
residue in this position. Residue 324 in gpl20 is Phe in 73% and 
hydrophobic in 98.7% ofgpl20 sequences. This sequence com- 
parison indicates that in the vast majority of HIV isolates, 
gp120 has hydrophobic residues that could potentially partici- 
pate in hydrophobic nteractions that stabilize a loop similar to 
that observed for RP135a. Since the peptide RP135a of the 
HIV-lmB isolate contains an insertion of two residues (Gln-7 
and Arg-8) that appear in only 4% of gp 120 sequences [18], this 
loop may be 2-residues shorter in gpl20 of other strains. The 
NOESY difference spectroscopy presented in this study could 
be implemented for comparative studies of complexes of anti° 
gp120 antibodies recognizing the PND of other HIV strains to 
find out whether the loop found in this study for the HIV-1HI B 
strain is indeed widespread among HIV isolates. 
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